Proceedings: A correlation between the response to debrisoquine and the amount of unchanged drug excreted in the urine.
作者信息
Angelo M, Dring L G, Lancaster R, Latham A, Smith R L
出版信息
Br J Pharmacol. 1975 Oct;55(2):264P.
Abstract
摘要
相似文献
1
2
Clinical trials with Tendor (debrisoquine sulfate).
Ther Hung. 1974;22(4):165-71.
3
[On the hypotensive effect of debrisoquin sulfate (Declinax)].[关于硫酸地昔帕明（Declinax）的降压作用]
Rev Med Univ Navarra. 1973 Dec;17(4):339-44.
4
A longitudinal study of the mechanisms of action of debrisoquine and propranolol.关于异喹胍和普萘洛尔作用机制的纵向研究。
Br J Clin Pharmacol. 1978 Jul;6(1):43-50. doi: 10.1111/j.1365-2125.1978.tb01680.x.
5
Why hypertensive patients vary in their response to oral debrisoquine.为何高血压患者对口服异喹胍的反应存在差异。
Br Med J. 1977 Feb 12;1(6058):422-5. doi: 10.1136/bmj.1.6058.422.
6
Hypotensive response to debrisoquine and hydroxylation phenotype.
Life Sci. 1978 Mar;22(11):979-83. doi: 10.1016/0024-3205(78)90363-6.
7
Interaction between debrisoquine and phenylephrine in man.人体内异喹胍与去氧肾上腺素之间的相互作用。
Br J Pharmacol. 1973 Mar;47(3):675P-676P.
8
Metabolism of debrisoquine sulfate. Identification of some urinary metabolites in rat and man.
Drug Metab Dispos. 1975 Sep-Oct;3(5):332-7.
9
A study of the debrisoquine hydroxylation polymorphism in a Nigerian population.尼日利亚人群中异喹胍羟基化多态性的研究。
Xenobiotica. 1980 Nov;10(11):811-8. doi: 10.3109/00498258009033811.
10
Proceedings: Parasympathetic blockade in patients treated with debrisoquine and with propranolol.论文集：用异喹胍和普萘洛尔治疗的患者中的副交感神经阻滞
West Afr J Pharmacol Drug Res. 1974 Dec;2(1):53P-54P.
引用本文的文献
1
Importance of Publishing Adverse Drug Reaction Case Reports: Promoting Public Health and Advancing Pharmacology and Therapeutics.发表药品不良反应病例报告的重要性：促进公众健康并推动药理学与治疗学发展
Drug Saf Case Rep. 2017 Sep 20;4(1):11. doi: 10.1007/s40800-017-0053-0.
2
Personalized medicine - where do we stand? Pouring some water into wine: a realistic perspective.个性化医疗——我们现状如何？往酒里掺水：一个现实的视角。
Croat Med J. 2012 Aug;53(4):314-20. doi: 10.3325/cmj.2012.53.314.
3
3,4-Dehydrodebrisoquine, a novel debrisoquine metabolite formed from 4-hydroxydebrisoquine that affects the CYP2D6 metabolic ratio.3,4-脱氢去甲丙咪嗪，一种由4-羟基去甲丙咪嗪形成的新型去甲丙咪嗪代谢物，它会影响CYP2D6代谢率。
Drug Metab Dispos. 2006 Sep;34(9):1563-74. doi: 10.1124/dmd.105.008920. Epub 2006 Jun 16.
4
Polymorphic drug oxidation: pharmacokinetic basis and comparison of experimental indices.多态性药物氧化：药代动力学基础及实验指标比较
Br J Clin Pharmacol. 1986 Nov;22(5):541-50. doi: 10.1111/j.1365-2125.1986.tb02933.x.
5
The metabolism of [14C]-debrisoquine in man.人体中[14C]-异喹胍的代谢
Br J Clin Pharmacol. 1979 Mar;7(3):257-66. doi: 10.1111/j.1365-2125.1979.tb00930.x.
本文引用的文献
1
Quantitative determination of guanethidine and other guanido-containing drugs in biological fluids by gas chromatography with flame ionization detection and multiple ion detection.采用火焰离子化检测和多离子检测气相色谱法定量测定生物流体中的胍乙啶及其他含胍基药物。
Anal Chem. 1974 Jan;46(1):34-9. doi: 10.1021/ac60337a045.
Zotero 插件